Vitamin D for multiple sclerosis as an adjuvant therapy: A network meta-analysis of randomized controlled trials
Zhuang Y, Meng J, Dai X, He M, Liu P, Gao S
Clinical nutrition (Edinburgh, Scotland) · 0 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Natural Science Foundation of China
- Universidad u hospital
- Central South University
- Gobierno
- Natural Science Foundation of Hunan Province
- Gobierno
- Natural Science Foundation for Young Scientists of Shanxi Province
- Universidad u hospital
- Xiangya Hospital, Central South University
- Gobierno
- Hunan Provincial Natural Science Foundation
- Subvenciones
- Central South University (2021KFJJ06); Natural Science Foundation of Hunan Province (2021JJ30040); National Natural Science Foundation of China (81672225)
Según 6 financiadores declarados.
Publicación
- Publicado
- 2026-05-26 · Clin Nutr · vol. 62 · pág. 106692
- Editorial
- Elsevier BV
- Citado
- 0 citas · más que el 29% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 47 trabajos
- Acceso
- De pago
- Áreas de investigación
- Multiple Sclerosis Research Studies · Vitamin D Research Studies · Psoriasis: Treatment and Pathogenesis
- Palabras clave
- vitamin D supplementation, multiple sclerosis, adjuvant therapy, relapse risk, disability progression, Expanded Disability Status Scale, annualized relapse rate, immunomodulation, vitamin D deficiency, adverse events
- MeSH
- humans, multiple sclerosis, vitamins, vitamin d, treatment outcome, dietary supplements, adult, female, randomized controlled trials as topic
6 autores
- Yuheng Zhuang🇨🇳Central South University; Xiangya Hospital Central South University
- Jiahao Meng🇨🇳Xiangya Hospital Central South University
- Xingui Dai🇨🇳Chenzhou First People's Hospital
- Miao He🇨🇳Second Xiangya Hospital of Central South University
- Pan Liu🇨🇳Xiangya Hospital Central South University
- Shuguang Gao🇨🇳 · autor de correspondenciaXiangya Hospital Central South University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system, with limited effective adjuvant therapies beyond immunomodulatory agents. Vitamin D supplementation has been proposed as a potential adjunct treatment due to its immunomodulatory properties. We aimed to evaluate the efficacy and safety of vitamin D supplementation as an adjuvant therapy for patients with MS.
Methods
We conducted a network meta-analysis of randomized controlled trials comparing vitamin D supplementation (any form or dose) plus standard care versus standard care alone or with placebo in adults with MS. We searched PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trial registries from inception to January 31, 2026. We performed frequentist random-effects network meta-analyses and used the GRADE framework to assess the certainty of evidence.
Results
An analysis of 32 RCTs involving 2254 MS patients showed that compared with placebo, Long-term follow-up vitamin D intervention significantly reduced relapse risk (RR 0.80), improved EDSS scores (MD -0.22). Network meta-analysis revealed high-dose long-duration vitamin D supplementation was the most effective for EDSS scores (MD -0.28; 95% CI -0.54 to -0.03) and relapse (RR 0.76; 95% CI 0.59 to 0.98) compared with placebo. Mid-dose long-duration supplementation showed favorable effects on ARR. For safety, no significant difference in SAEs was observed (RR 1.49; 95% CI 0.94 to 2.37).
Conclusion
Vitamin D supplementation as an adjuvant therapy may reduce relapse and disability progression, with a favorable safety profile. These findings support the consideration of vitamin D supplementation in MS management, particularly in deficient populations.
Study registration
PROSPERO CRD420251163641.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.